SCHEMBL3751397

SCHEMBL3751397

CCc1nc(-c2ncccn2)sc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.46
KMT2A Q03164 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.41
PDE4A P27815 1/20 0.40
LMNA P02545 1/20 0.38
RAB9A P51151 3/20 0.37
NPC1 O15118 3/20 0.37
MEN1 O00255 2/20 0.37
CDC7 O00311 3/20 0.37
DBF4 Q9UBU7 3/20 0.37
GAA P10253 2/20 0.36
ALDH1A1 P00352 1/20 0.36
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26795528 0.88 TRPM8 (0.39) KDM4EKMT2ASMN1; SMN2PDE4ALMNA
SCHEMBL26791923 0.85 TRPM8 (0.38) KDM4EKMT2ASMN1; SMN2PDE4ALMNA
SCHEMBL16702679 0.81 SMN1; SMN2 (0.64) KDM4EKMT2ASMN1; SMN2LMNARAB9A
SCHEMBL5735278 0.78 CDC7 (0.61) KDM4ESMN1; SMN2RAB9ACDC7DBF4
SCHEMBL13043130 0.78 KDM4E (0.69) KDM4EKMT2ASMN1; SMN2LMNARAB9A
SCHEMBL3749715 0.78 ALDH1A1 (0.45) KDM4EKMT2ASMN1; SMN2LMNAMEN1
SCHEMBL3742906 0.78 ALDH1A1 (0.45) KDM4EKMT2ASMN1; SMN2LMNAMEN1
SCHEMBL3747362 0.78 NAMPT (0.39) KDM4ERAB9ANPC1GAAHPGD
SCHEMBL5734672 0.77 CYP1A2 (0.56) KDM4EKMT2ASMN1; SMN2LMNAMEN1
SCHEMBL7687407 0.76 SMN1; SMN2 (0.43) KDM4EKMT2ASMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133204-B2 5-membered heterocyclic amides and related compounds H. LUNDBECK A/S (DK) 2015-09-15 US disclosed
US-9133204-B2 5-membered heterocyclic amides and related compounds H. LUNDBECK A/S (DK) 2015-09-15 US disclosed
US-9133204-B2 5-membered heterocyclic amides and related compounds H. LUNDBECK A/S (DK) 2015-09-15 US disclosed
EP-2178865-B1 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS LUNDBECK H AS (DK) 2015-08-19 EP disclosed
US-20150005293-A1 5-Membered Heterocyclic Amides And Related Compounds MINDIMMUNE THERAPEUTICS, INC. 2015-01-01 US disclosed
US-20150005293-A1 5-Membered Heterocyclic Amides And Related Compounds MINDIMMUNE THERAPEUTICS, INC. 2015-01-01 US disclosed
US-20150005293-A1 5-Membered Heterocyclic Amides And Related Compounds MINDIMMUNE THERAPEUTICS, INC. 2015-01-01 US disclosed
US-20100292236-A1 5-Membered Heterocyclic Amides And Related Compounds H. LUNDBECK A/S (DK) 2010-11-18 US disclosed
US-20100292236-A1 5-Membered Heterocyclic Amides And Related Compounds H. LUNDBECK A/S (DK) 2010-11-18 US disclosed
US-20100292236-A1 5-Membered Heterocyclic Amides And Related Compounds H. LUNDBECK A/S (DK) 2010-11-18 US disclosed
WO-2009012482-A2 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS H.LUNDBECK A/S (DK) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150005293-A1 5-Membered Heterocyclic Amides And Related Compounds GPR35, HCAR2, HCAR1 KDM4E 3311/4885KMT2A 3781/4885SMN1; SMN2 3228/4885
US-20100292236-A1 5-Membered Heterocyclic Amides And Related Compounds GPR35, HCAR2, HCAR1 KDM4E 3311/4885KMT2A 3781/4885SMN1; SMN2 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.